Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years

Abstract

Background: The design and development of prodrugs is the most common and effective strategy to overcome pharmacokinetic and pharmacodynamic drawbacks of active drugs. A respected number of prodrugs have been reached the drugs market throughout history and the recent years have witnessed a significant increase in the use of prodrugs as a replacement of their parent drugs for an efficient treatment of various ailment. Methods: A Scan conducted to find recent approved prodrugs and prodrugs in development. Results: Selected prodrugs were reported and categorized in accordance to their target systems. Conclusions: the prodrug approach has shown many successes and still remains a viable and effective approach to deliver new active agents. This conclusion is supported by the recent approved prodrugs and the scan of clinical trials conducted between 2013–2018.

Thapsigargin—From Traditional Medicine to Anticancer Drug

“…Prodrugs are inactive compounds that, in the body, are transformed into pharmacologically active therapeutics [59]. The Tg-based prodrug strategy utilizes the proteolytic enzymes that are preferentially expressed on the surface of cancer cells or are secreted by cells of solid tumors.…”

An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies

“…The many functions of Sigma1R that are related to the pathology of DEEs and to central nervous system (CNS) physiology suggest a potential role for Sigma1R in the DEE pathophysiology of seizures and in aspects of higher cognitive function. For example, ANAVEX 2-73 (blarcamesine), which has agonist activity both at the Sigma1R and at muscarinic receptors, is currently in clinical trials for neurodegenerative diseases (NCT03774459, NCT03790709; Alzheimer's disease, Parkinson's disease dementia, and Rett syndrome (which manifests with seizures in most patients)) and was granted FDA's Orphan Drug Designation for infantile spasms in 2016 [41,42,[54][55][56][57].…”

Enhancement strategies for transdermal drug delivery systems: current trends and applications

“…For instance, a prodrug may result in toxicity because of unpredictable metabolism, potentially leading to the production of toxic metabolites [ 88 ]. Moreover, it is imperative to assess the toxicity of the linking agent (inactive moiety) and the prodrug itself, due to the possibility of toxic side products upon synthesis [ 89 ]. Furthermore, the production of a prodrug requires complex fabrication considerations/methods and is limited only to the generation of small molecules [ 10 ].…”